Head & neck · 2026
Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kano Satoshi, Kawakita Daisuke, Honma Yoshitaka, Takahashi Hideaki, Hanazawa Toyoyuki, Tsukahara Kiyoaki, Fujii Shota, Okami Kenji, Yamazaki Keisuke, Ueki Yushi, Saito Yuki, Ozawa Hiroyuki, Imaizumi Sae, Arai Tomoyuki, Iwaki Sho, Hanyu Kenji, Yamauchi Mayu, Tanaka Ryoko, Yamamura Koji, Sekimizu Mariko, Fushimi Chihiro, Matsuki Takashi, Utsumi Yoshitaka, Nakaguro Masato, Nagao Toshitaka, Tada Yuichiro, Multi‐institutional Joint SDC Study Group in Japan
Аннотация
BACKGROUND: Optimal treatment for non-metastatic unresectable salivary duct carcinoma (SDC) remains unclear. We compared outcomes of upfront biomarker-targeted systemic therapy and radiotherapy.
METHODS: We retrospectively analyzed the Joint SDC Study Group registry. Thirty-one patients with centrally confirmed non-metastatic unresectable SDC were classified by initial treatment (radiotherapy or systemic therapy). Systemic therapy included trastuzumab plus docetaxel, combined androgen blockade, or chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed.
RESULTS: Systemic therapy showed better PFS than radiotherapy (3-year PFS 47.6% vs. 30.0%, p = 0.031) without OS difference. Trastuzumab plus docetaxel showed the highest response rate (75%) and enabled curative-intent treatment in all cases, with the best PFS (3-year 87.5%, p = 0.012).
CONCLUSIONS: Given the retrospective design and limited sample size, these findings should be regarded as hypothesis-generating. An upfront trastuzumab-based therapy followed by curative-intent treatment may be a promising option for selected patients with HER2-positive unresectable SDC.
METHODS: We retrospectively analyzed the Joint SDC Study Group registry. Thirty-one patients with centrally confirmed non-metastatic unresectable SDC were classified by initial treatment (radiotherapy or systemic therapy). Systemic therapy included trastuzumab plus docetaxel, combined androgen blockade, or chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed.
RESULTS: Systemic therapy showed better PFS than radiotherapy (3-year PFS 47.6% vs. 30.0%, p = 0.031) without OS difference. Trastuzumab plus docetaxel showed the highest response rate (75%) and enabled curative-intent treatment in all cases, with the best PFS (3-year 87.5%, p = 0.012).
CONCLUSIONS: Given the retrospective design and limited sample size, these findings should be regarded as hypothesis-generating. An upfront trastuzumab-based therapy followed by curative-intent treatment may be a promising option for selected patients with HER2-positive unresectable SDC.